← Eichor
Study identifier: NCT04799002 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Topotecan and Melphalan for Retinoblastoma

Condition: Retinoblastoma · Chemotherapy Effect  ·  Sponsor: Sun Yat-sen University

PhasePhase 3
Planned participants50
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

This description comes directly from the study's public registry record.

Talk to the study team

Huasheng Yang  ·  +00862087331539  ·  yanghs64@126.com

Huijing Ye  ·  +00862087331539  ·  yehuijing@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04799002